A Phase 1/2 Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer
Phase of Trial: Phase I/II
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Cemiplimab (Primary) ; REGN 4018 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 07 Nov 2018 Planned End Date changed from 21 Apr 2022 to 5 May 2022.
- 07 Nov 2018 Planned primary completion date changed from 21 Apr 2022 to 5 May 2022.
- 26 Jun 2018 New trial record